abaloparatide


( Last Updated : August 3, 2022)
Generic Name:
abaloparatide
Project Status:
Received
Therapeutic Area:
Osteoporosis, postmenopausal women
Manufacturer:
Paladin Labs Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0744-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of osteoporosis in postmenopausal women at high risk of fracture or who have failed on other available osteoporosis therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of osteoporosis in postmenopausal women at high risk of fracture or who have failed or are intolerant to other available osteoporosis therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open04-Jul-22
Call for patient/clinician input closed26-Aug-22
Submission received02-Aug-22
Submission accepted